Summary
The extracted claims concern patent expiry, exclusivity, litigation, and jurisdictional timing. The provided FDA label excerpt contains only a general 'Patent Information' link and does not support any of these patent/legal timing statements.
Category Scores
Accurate Statements
Unsupported Statements
The specific date of Wegovy patent expiry depends on which patent is meant (active ingredient, specific formulations, manufacturing processes, or method-of-use).
The provided label excerpt does not describe how patent expiry dates depend on patent type (active ingredient vs formulations/manufacturing/method-of-use).
Wegovy (semaglutide) is protected by multiple patent families.
The provided label excerpt does not state that Wegovy is protected by multiple patent families.
Patent expiry does not necessarily mean Wegovy will face generic competition immediately.
The provided label excerpt does not address timing of generic competition relative to patent expiry.
Even after patents expire, market entry can be blocked by other still-active patents in the same product/patent family.
The provided label excerpt does not discuss post-expiry market-entry blocking by other active patents.
Even after patents expire, regulatory exclusivity periods can block market entry (if applicable).
The provided label excerpt does not mention regulatory exclusivity periods or their effect on market entry.
Even after patents expire, ongoing litigation or “skinny-label/labeling” disputes can block market entry.
The provided label excerpt does not discuss litigation, 'skinny-label', or labeling disputes affecting market entry.
The first generic or biosimilar timeline is often later than the earliest patent expiry.
The provided label excerpt does not discuss generic/biosimilar launch timelines relative to patent expiry.
Patent term, granted patents, and exclusivity rules vary by jurisdiction.
The provided label excerpt does not address jurisdictional variation in patent terms, granted patents, or exclusivity rules.
Wegovy’s launch and legal protection in the U.S. may have different expiry dates than in the EU, UK, or other countries.
The provided label excerpt does not provide international (EU/UK/other) patent expiry comparisons.
Contradictions
Important Omissions
FDA label support for the legal/patent-timing claims (patent expiry date mechanics, exclusivity, litigation/skinny-label, and jurisdictional differences) is not present in the provided excerpt.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The claims are about patent/legal timing rather than direct patient safety, dosing, contraindications, or clinical risks. However, they are unsupported by the provided label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All extracted statements about patent expiry, exclusivity, litigation, and jurisdictional differences are unsupported by the provided FDA label excerpt.
Suggested Improvement
Remove these legal/patent-timing claims or cite label language that explicitly addresses patent/exclusivity-related timing; otherwise do not present them as label-supported.